RT Journal Article
SR Electronic
T1 Emergence of universality in the transmission dynamics of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.29.21250750
DO 10.1101/2021.01.29.21250750
A1 Ayan Paul
A1 Jayanta Kumar Bhattacharjee
A1 Akshay Pal
A1 Sagar Chakraborty
YR 2021
UL http://medrxiv.org/content/early/2021/02/03/2021.01.29.21250750.abstract
AB The complexities involved in modeling the transmission dynamics of COVID-19 has been a major roadblock in achieving predictability in the spread and containment of the disease. In addition to understanding the modes of transmission, the effectiveness of the mitigation methods also needs to be built into any effective model for making such predictions. We show that such complexities can be circumvented by appealing to scaling principles which lead to the emergence of universality in the transmission dynamics of the disease. The ensuing data collapse renders the transmission dynamics largely independent of geopolitical variations, the effectiveness of various mitigation strategies, population demographics, etc. We propose a simple two-parameter model—the Blue Sky model—and show that one class of transmission dynamics can be explained by a solution that lives at the edge of a blue sky bifurcation. In addition, the data collapse leads to an enhanced degree of predictability in the disease spread for several geographical scales which can also be realized in a model-independent manner as we show using a deep neural network. The methodology adopted in this work can potentially be applied to the transmission of other infectious diseases and new universality classes may be found. The predictability in transmission dynamics and the simplicity of our methodology can help in building policies for exit strategies and mitigation methods during a pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll codes and data necessary to reproduce the results can be found at: https://github.com/talismanbrandi/Universality-COVID-19 https://github.com/talismanbrandi/Universality-COVID-19